Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated November 25, 2024, reports on the company's ongoing share repurchase programme. Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 72,000 people across 80 countries. The filing details transactions executed under a programme initiated on November 11, 2024, which is part of a broader 12-month repurchase plan authorized to begin on February 6, 2024.
Key Financial Metrics
The filing focuses on capital allocation via share buybacks rather than operational financial performance. Key metrics include:
- Share Repurchase Programme Cap: Up to DKK 20 billion over a 12-month period starting February 6, 2024.
- Specific Programme (Nov 11, 2024): Authorized up to DKK 3,136,206,122.30 for the period ending February 3, 2025.
- Total Repurchased (Since Feb 6, 2024): 21,035,086 B shares at an average price of DKK 830.77, totaling DKK 17,475,418,304 as of November 22, 2024.
- Treasury Shares: The company holds 22,179,644 B shares as treasury shares, representing 0.5% of total share capital.
- Total Share Capital: 4,465,000,000 A and B shares (including treasury shares).
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes
Since the last announcement on November 18, 2024, the company executed daily repurchases of 80,000 B shares from November 19 to November 22, 2024. The average purchase price for these recent transactions ranged between DKK 707.75 and DKK 738.07. The accumulated transaction value under the specific November 11 programme reached DKK 611,624,426 as of November 22, 2024.
Guidance, Outlook, and Risks
Management expects to continue repurchasing B shares up to the DKK 20 billion limit during the 12-month period beginning February 6, 2024. The repurchases are conducted in accordance with the EU Market Abuse Regulation (MAR) and Safe Harbour Rules. The filing does not contain specific guidance on future earnings, operational risks, or contingencies beyond the standard execution of the buyback programme.
Investor Verification Checklist
- Verify the remaining capacity under the DKK 20 billion total repurchase programme (approximately DKK 2.5 billion remaining as of Nov 22, 2024).
- Confirm the current market price of B shares relative to the recent average purchase price of DKK 830.77.
- Review the full list of daily transactions on the company's official website (novonordisk.com) for updates beyond November 22, 2024.
- Check the latest Form 20-F or quarterly reports for operational financial metrics (revenue, profit, cash flow) not included in this 6-K.